Arcturus Therapeutics to Report Identification of
LUNAR-HBV, a Potent Combination of Three UNA Oligomers Targeting All Hepatitis B Virus Genotypes at the AASLD Liver MeetingĀ® 2016
SAN DIEGO, Oct 3, 2016 /PRNewswire/ -- Arcturus Therapeutics, Inc. ("Arcturus" or the "Company"), a leading RNA medicines company, announced today that preclinical data for a multi-siRNA treatment of Chronic Hepatitis B Virus (HBV), developed in collaboration with Janssen Pharmaceuticals, Inc.